explore -WSS

explore

author：leisure time 2025-10-01 01:49:15 - browse：554

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

WSS

Anesthesiologist group: stop taking Ozempic before surgery

Medicare details structure of new drug price negotiation program

Stroke deaths set to near 10 million globally by 2050

The future of health care in the House

In age of alternative facts, a scholarly course on calling out crap

Apple is now the first public company to be valued at $3 trillion

focus

explore

The next ALS data readout — overdue but important

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Senate panel eyes new effort on drug shortages

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How to save PrEP access — and even expand it

Duchenne breakthrough therapy leaves behind pioneering families

Medicare details structure of new drug price negotiation program

As demand for Covid shots wanes, Moderna seeks its next success

Medical leaders decry Supreme Court decision on affirmative action

Wikipedia

FDA authorizes Novavax’s updated Covid

FDA rejects Alnylam's heart disease treatment over insufficient data

Stroke deaths set to near 10 million globally by 2050

FDA panel signals lack of confidence in Amgen cancer drug data

The future of health care in the House

Psychedelics group wrestles with new pharma identity

knowledge

Wikipedia

hotspot

explore